fool.com · 4 jul

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying

Viking Therapeutics is studying its weight loss drug candidate in late-stage trials. If all goes smoothly, the biotech could enter a market nearing $100 billion in the next few years.

fool.com · 3 jul

Here's Why Viking Therapeutics Stock Surged Higher in June

Viking's VK2735 has advantages over other weight-loss drugs, and investors anticipate positive results from Phase 3 trials in the coming years. The development of VK2735 as a dual formulation therapy could be the key to unlocking value for investors.

zacks.com · 1 jul

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting a -3.92% move from the preceding trading day.

fool.com · 1 jul

Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics' pipeline includes several promising weight-loss candidates. The stock could soar in the next 18 months, but there is plenty of risk involved.

seekingalpha.com · 30 jun

Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate

Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk's oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs' commercial potential and raising the value of VKTX's oral program. VKTX's injectable VK2735 faces intensified competition after Eli Lilly's Retatrutide Phase III results, which establish a higher efficacy standard (>24%).

zacks.com · 29 jun

Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.

zacks.com · 29 jun

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

fool.com · 29 jun

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could

Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.